Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy (RELEASE)

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: Budesonide/formoterol; Device: Symbicort® Turbohaler®

Study type: Interventional

Funder types: Industry

Identifiers

NCT00319306

D5890L00012

RELEASE

Details and patient eligibility

About

The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged over 18
• Confirmed diagnosis of mild to moderate asthma by doctor
• Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment

Exclusion criteria

• Women who are pregnant, breast-feeding, or planning pregnancy
• Patients with a history of chronic obstructive pulmonary disease
• Patients using any beta blocker therapy
• Patients receiving steroid tablets or steroid injections

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)